- InspirMed Inc presented data on the potential advantages of inhalable liposome formulations of antiviral drugs at the International Society for Aerosols in Medicine Congress.
- InspirMed is a subsidiary of Taiwan Liposome Company TLC, specializing in developing inhalable liposome formulation programs for severe acute and chronic pulmonary diseases.
- Pharmacokinetic studies on inhalable liposomal GS-441524 (ISPM21) and inhalable liposomal hydroxychloroquine (ISPM19) showed significantly higher lung concentrations than their conventional counterparts, giving the candidates the potential as prophylaxis and treatment for COVID-19.
- GS-441524 is the main plasma metabolite of the antiviral prodrug remdesivir, which is approved in the US for COVID-19. GS-441524 holds several advantages over remdesivir, with better safety and efficacy profiles.
- Intratracheally administered ISPM21 had a long half-life of 22.8 hours, with significantly higher concentrations (over 200-fold) in the lung and comparable systemic exposure in the plasma than an equal dose of intravenously administered GS-441524 solution.
- At just 1% of the proposed oral dose of hydroxychloroquine to treat COVID-19, intratracheally administered ISPM19 had a longer half-life (around 2.5-fold) and higher exposure in the lung (~30-fold) than intravenously administered free hydroxychloroquine.
- ISPM19 nebulized into an aerosol exhibited a lung deposition rate (inhaled dose) of 26.67%.
- Price Action: TLC shares are up 3.3% at $4.4 during the premarket session on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
